- Home
- MNOV vs CTSO Comparison
MNOV vs CTSO Comparison
Compare MNOV & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNOV
- CTSO
- Stock Information
- Founded
- MNOV 2000
- CTSO 1997
- Country
- MNOV United States
- CTSO United States
- Employees
- MNOV N/A
- CTSO N/A
- Industry
- MNOV Biotechnology: Pharmaceutical Preparations
- CTSO Medical/Dental Instruments
- Sector
- MNOV Health Care
- CTSO Health Care
- Exchange
- MNOV Nasdaq
- CTSO Nasdaq
- Market Cap
- MNOV 73.1M
- CTSO 68.2M
- IPO Year
- MNOV 2005
- CTSO N/A
- Fundamental
- Price
- MNOV $1.41
- CTSO $0.85
- Analyst Decision
- MNOV Strong Buy
- CTSO Buy
- Analyst Count
- MNOV 1
- CTSO 2
- Target Price
- MNOV $9.00
- CTSO $5.50
- AVG Volume (30 Days)
- MNOV 11.3K
- CTSO 149.6K
- Earning Date
- MNOV 05-13-2025
- CTSO 05-14-2025
- Dividend Yield
- MNOV N/A
- CTSO N/A
- EPS Growth
- MNOV N/A
- CTSO N/A
- EPS
- MNOV N/A
- CTSO N/A
- Revenue
- MNOV N/A
- CTSO $35,332,238.00
- Revenue This Year
- MNOV N/A
- CTSO $18.72
- Revenue Next Year
- MNOV N/A
- CTSO $19.75
- P/E Ratio
- MNOV N/A
- CTSO N/A
- Revenue Growth
- MNOV N/A
- CTSO N/A
- 52 Week Low
- MNOV $1.12
- CTSO $0.70
- 52 Week High
- MNOV $2.55
- CTSO $1.61
- Technical
- Relative Strength Index (RSI)
- MNOV 47.13
- CTSO 39.76
- Support Level
- MNOV $1.34
- CTSO $0.82
- Resistance Level
- MNOV $1.45
- CTSO $0.90
- Average True Range (ATR)
- MNOV 0.07
- CTSO 0.05
- MACD
- MNOV -0.01
- CTSO -0.00
- Stochastic Oscillator
- MNOV 52.17
- CTSO 34.11
About MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's current strategy is to focus its development activities on therapeutics for neurological disorders and fibrotic diseases.
About CTSO Cytosorbents Corporation
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.